Home Compliance Novartis’ and Alcon’s $345 Million FCPA Case Signals Increased Scrutiny of Gifts... ComplianceExpert OpinionFCPANews Novartis’ and Alcon’s $345 Million FCPA Case Signals Increased Scrutiny of Gifts and Entertainment and Renewed Focus on Scientific Studies July 24, 2020 45 Share FacebookLinkedinTwitter Taljat David | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Compliance False Claims Act Enforcement Trends in Healthcare: FY 2024 Law Amid Uncertainty, Government Contractors Should Document, Notify, and Escalate Claims Law Two Federal Courts Order Trump Administration To Unfreeze Funding
